The 15th International Symposium on Anti-Angiogenic Therapy: Recent Advances and Future Directions in Basic and Clinical Care Research
ANGIO 2013 The 15th International Symposium on Anti-Angiogenic Therapy: Recent Advances and Future Directions in Basic and Clinical Cancer Research January 31–February 2, 2013Hyatt Regency La Jolla • 3777 La Jolla Village Drive • San Diego, California www.antiangio2013.com For Information and Poster Submission Form
Evaluation POSTERProgram Overview A course evaluation form will provide participants with SUBMISSION/ the opportunity to comment on the value of the programAngiogenesis is an essential process in the growth of neoplasms and progression to metastasis.The angiogenic pathway is orchestrated by a range of pro- and anti-angiogenic factors that ultimately content to their practice decisions, performance improve- SESSION: ment activities, or possible impact on patient health status.lead to the development of a neovascular blood supply to the tumor mass. Vascular endothelial growth Participants will also have the opportunity to comment onfactor (VEGF), which stimulates proliferation and migration of endothelial cells, plays a pivotal role in The symposium will feature any perceived commercial bias in the presentations as well a poster session wherethis process. For these reasons, the inhibition of VEGF and its receptor signaling system are attractive as to identify future educational topics.targets for therapeutic intervention. Indeed, the approval in 2004 of a neutralizing monoclonal academics and investigatorsantibody directed against VEGF – the first anti-angiogenic systemic drug to treat cancer patients- from the industry presentvalidated the notion introduced decades earlier that inhibition of tumor angiogenesis may be a valid Accreditation/Credit Designation angiogenesis-related dataapproach to control tumor growth. This success has driven the search for new anti-angiogenic agents. The University of Texas MD Anderson Cancer Center is from both clinical trials andFor example, small-molecule multikinase inhibitors that target VEGF receptors have recently demon- accredited by the Accreditation Council for Continuing laboratory research.strated efficacy in multiple tumor types. A number of other anti-angiogenic agents targeting an Medical Education to provide continuing medical education Trainees are especiallyincreasing variety of molecular tumor features are in clinical development. More recently, studies of for physicians. encouraged to presentpowerful new genetic and cell biological approaches have provided unprecedented insights into how their research. Accepted The University of Texas MD Anderson Cancer Center posters will be displayed withvarious molecular are pivotal to tumor growth and survival. As a consequence, a number of new designates this live activity for a maximum of 14.50 ample time for viewing andangiogenic molecules, such as neuropilins, Tie-2, and Notch ligand delta-like 4, have emerged as AMA PRA Category 1 CreditsTM. Physicians should claimpromising targets. discussions only the credit commensurate with the extent of theirSince its inception over 4 decades ago, investigators in the field of tumor angiogenesis research have participation in the activity. All symposium participants,made significant progress. Advancements in therapeutics have altered cancer treatment paradigms, including members ofand the next decade promises to be an exciting and productive time. This annual state-of-the-artsymposium is designed to continue the dialogue and interaction between research and clinical CME Certificates and industry, are encouraged to present research data as partinvestigators by reviewing the current scientific understanding of vascular biology and angiogenesis. Attendance Verification Certificates of the poster session.In addition, this symposium provides a forum for presenting the most current preclinical and clinical Certificates awarding AMA PRA Category 1 Credit TMdata on emerging anti-angiogenic agents and regimens. Strategies that inhibit angiogenesis in or certificates documenting attendance will becolorectal, breast, lung, esophageal, gastric, genitourinary, neuroendocrine, central nervous system, The deadline for submitting distributed to participants when an individual departshepatocellular and gynecologic malignancies will be discussed. In addition, biomarkers and resistance the conference. To obtain a CME certificate, physicians poster applications ispathways will be addressed and controversies in the field will be highlighted. Friday, December 14, 2012. must submit a completed evaluation questionnaire and a CME Verification Form.Educational Objectives Upon request, a record of attendance (certificate) will be Please check the websiteAfter attending the symposium, participants should be able to provided on-site to other health care professionals for for more information and• Define angiogenesis and its relevance to the treatment of cancer (Knowledge); requesting credits in accordance with state nursing boards,• Outline the rationale for the development of anti-angiogeneic agents, and explain why specialty societies, or other professional associations. the submission form at angiogenic signaling pathways are targets for inhibition (Knowledge); www.antiangio2013.com.• Summarize data from clinical trials that support the use of currently available anti-angiogenic agents as monotherapy or in combination with other therapeutic modalities, which will ultimately assist the healthcare provider to make appropriate clinical decisions (Knowledge, Planning Committee Competence, Performance, Patient Outcomes); Lee M. Ellis, MD George W. Sledge, Jr., MD Professor of Surgery and Cancer Biology Ballve-Lantero Professor of OncologyTarget Audience William C. Liedtke, Jr., Chair in Cancer Research The University of Texas MD Anderson Cancer Center Co-Director, Breast Cancer Program Indiana University Melvin and Ben Simon Cancer CenterThis symposium is designed for medical, surgical, and radiation oncologists, pharmacists, other Houston, Texas Indianapolis, Indianaproviders of cancer care (PAs, RNs, etc.), and research scientists who have an interest in thebiology, diagnosis, and treatment of cancer, as well as those who diagnose and treat patients with Robert S. Kerbel, PhD Helen X. Chen, MD Canada Research Chair in Tumor Biology, Senior Investigator in Cancer Therapynonmalignant vascular diseases, such as arthritis and retinal neovascularization. As new and Evaluation Program Angiogenesis and Anti-Angiogenic Therapyemerging data on anti-angiogenic therapy is presented at this symposium every year, it is necessary National Cancer Institute University of Torontofor this audience to be made aware of these findings so they can be utilized in their clinical practice. Professor, Molecular and Cellular Rockville, Maryland Biology Research Axel Grothey, MDEducational Methods Sunnybrook Health Sciences Centre/Odette Cancer Centre Professor of Oncology Division of Medical OncologyLectures – Panel Discussions – Question and Answer – Poster Session Toronto, Ontario, Canada Mayo Clinic Division of Medical Oncology Rochester, Minnesota
Program Session II: Biomarkers and Imaging Moderator: Robert S. Kerbel, PhD 1:00–1:25 Predictive Biomarkers: VEGF Amplifications and Host Polymorphisms Bryan P. Schneider, MDWednesday, January 30, 2013 1:25–1:50 Predictive Biomarkers: Imaging and Circulating VEGF Gordon Jayson, MD, PhD3:00–7:00 p.m. Registration 1:50–2:05 Abstract #2 2:05–2:30 Standardizing Imaging Criteria to Assess the Effect ofThursday, January 31, 2013 Anti VEGF Therapy in Brain Tumors Bradley J. Erickson, MD, PhD7:30–8:00 a.m. Registration/Continental Breakfast 2:30–2:55 The FDA Pre-IDE Process: Lessons Learned for Integral MarkersSession I: Basic Biology and Preclinical Data J. Milburn Jessup, MDModerator: Lee M. Ellis, MD; Robert S. Kerbel, PhD 2:55–3:15 Break8:00–8:30 Opening Remarks/Overview 3:15–3:45 Panel Discussion: Implementation of Biomarkers Lee M. Ellis, MD Moderator: Lee M. Ellis, MD Panelists: S. Gail Eckhardt, MD; Bradley J. Erickson, MD, PhD;8:30–8:55 Combinatorial Targeting of Endothelial Growth Factors Axel Grothey, MD; Gordon Jayson, MD, PhD; and Receptors J. Milburn Jessup, MD; Bryan P. Schneider, MD Kari Alitalo, MD, PhD 3:45–5:30 p.m. Poster Reception 8:55–9:20 Tumor Hypoxia: Is Targeting HIF a Viable Approach? M. Celeste Simon, PhD 9:20–9:45 Metronomic Chemotherapy with Anti-Angiogenic Drugs: Friday, February 1, 2013 An Update 7:30–8:00 a.m. Registration/Continental Breakfast Robert S. Kerbel, PhD Session III: Controversies and New Horizons9:45–10:10 Resistance to VEGF-Targeted Therapies Moderators: Axel Grothey, MD; George W. Sledge, Jr., MD TBD 8:00–8:05 Introduction10:10–10:30 Break George W. Sledge, Jr., MD 8:05–8:25 Is RECIST Still Relevant in the Era of VEGF Inhibition10:30–10:55 Anti-Angiogenic Agents Stimulate Breast Cancer Through Multiples Lines of Therapy? Stem Cells via Generation of Tumor Hypoxia Implications for Clinical Trial Design in All Malignancies Max S. Wicha, MD Axel Grothey, MD 10:55–11:10 Abstract #1 8:25– 8:50 Patient Derived Xenograft Models: Are They Appropriate For Anti-Angiogenic and Microenvironment Therapies?11:10–11:35 The Role of SDF-1/CXCR4 Signaling in Angiogenesis S. Gail Eckhardt, MD Martin Brown, DPhil 8:50–9:15 From the Laboratory to the Labrador: Spontaneous Canine11:35–Noon Oscillation of Immune Cells in Response to Cancer as a Model for Anti-Angiogenic Drug Development Anti-Angiogenic Therapy Douglas H. Thamm, VMC, DACVIM Gabriele Bergers, PhD 9:15–9:40 Promise and Pitfalls of Anti-Angiogenic TherapyNoon–1:00 p.m. Lunch in the Adjuvant Setting Daniel F. Hayes, MD
9:40–10:00 Break Saturday, February 2, 2013 Session IV: Early Drug Development 7:30–8:00 a.m. Registration/Continental BreakfastModerators: Helen X. Chen, MD; George W. Sledge, Jr., MD Session V: Clinical Trial Results10:00–10:15 Early Drug – Phase I Moderator: Axel Grothey, MD Michael S. Gordon, MD 8:00–8:05 Introduction10:15–10:30 Early Drug – Phase I Axel Grothey, MD Lee S. Rosen, MD10:30–10:45 Abstract #3 8:05–8:30 Clinical Overview and Perspectives on Anti-Angiogenic Therapy in CNS Tumors10:45–11:00 A Phase I Clinical Trial of VX15/2503, Patrick Y. Wen, MD A Novel Humanized IgG4 Anti-SEMA4D Antibody, In Patients With Advanced Solid Tumors 8:30–8:55 Antio-Angiogenic Therapy for the Treatment of Amita Patnaik, MD Neuroendocrine Tumors11:00–11:25 The Role of CTEP in the Development of Angiogenesis James C. Yao, MD Inhibitors Helen X. Chen, MD 8:55–9:10 Abstract #5 11:30–12:30 p.m. Lunch 9:10–9:35 Anti-Angiogenic Therapy for the Treatment of Lung Cancer Corey J. Langer, MDSession V: Clinical Trial Results 9:35–10:00 Anti-Angiogenic Therapy for the Treatment of Breast Cancer George W. Sledge, Jr., MDModerator: Helen X. Chen, MD; Michael S. Gordon, MD12:30-12:55 Anti-Angiogenic Therapy for the Treatment of 10:00 Closing Remarks Hepatocellular Carcinoma Ghassan K. Abou-Alfa, MD 10:15 Adjourn12:55–1:20 Anti-Angiogenic Therapy for the Treatment of Sarcoma Gary K. Schwartz, MD1:20–1:45 Anti-Angiogenic Therapy for the Treatment of Ovarian Cancer Gordon Jayson, MD, PhD1:45–2:05 Break2:05–2:30 Anti-Angiogenic Therapy for the Treatment of Colorectal Cancer Charles D. Blanke, MD2:30–2:45 Abstract #42:45–3:10 Anti-Angiogenic Therapy for the Treatment of Renal Cell Carcinoma Eric Jonasch, MD3:10–3:35 Vascular Disrupting Agents Gordon Rustin, MD3:35 Adjourn
Faculty Registration InformationGhassan K. Abou-Alfa, MD Michael S. Gordon, MD Gordon Rustin, MDAssociate Attending Professor Medical Oncology Director of Medical OncologyMemorial Sloan-Kettering Pinnacle Oncology Hematology Mount Vernon Cancer CentreCancer Center Scottsdale, Arizona Northwood, Middlesex On-site registration will be open from 3:00-7:00 p.m. on Wednesday, January 30,New York, New York United Kingdom Axel Grothey, MD 2013, and at 7:30 a.m. on Thursday, January 31. The conference will begin atKari Alitalo, MD, PhD Professor of OncologyResearch Professor of the Mayo Clinic College of Medicine Bryan P. Schneider, MD 8:00 a.m. on Thursday, January 31, and adjourn at 10:15 a.m. on Saturday, Associate ProfessorAcademy of Finland Rochester, Minnesota Indiana University Melvin and February 2. Advance registration is encouraged as space and materials areBiomedicum Helsinki Bren Simon Cancer Center limited. Please see registration form for applicable fees. Daniel F. Hayes, MDUniversity of Helsinki Indianapolis, Indiana Clinical DirectorHelsinki, Finland Breast Medical Oncology Program The deadline for advance registration is January 16, 2013. Stuart B. Padnos Professor Gary K. Schwartz, MDGabriele Bergers, PhD ChiefProfessor in Breast Cancer University of Michigan Melanoma and Sarcoma Service There are three ways to register:Brain Tumor Research Center Attending Physician Comprehensive Cancer CenterUniversity of California Ann Arbor, Michigan Memorial Sloan-Kettering • Mail to: CME/Conference Management–Unit 1381, The University of TexasSan Francisco Cancer CenterSan Francisco, California MD Anderson Cancer Center, P.O. Box 301439, Houston, TX 77230-1439 Gordon Jayson, MD, PhD New York, New York Professor of Medical Oncology • Fax to: 713-794-1724Charles D. Blanke, MD M. Celeste Simon, PhDVice-President The University of Manchester • On-line at www.mdanderson.org/conferences Withington, Manchester Professor of Cell andSystemic Therapy Developmental Biology United KingdomBritish Columbia Cancer Agency University of Pennsylvania We accept the following forms of payment:Professor & Chief, Medical Oncology J. Milburn Jessup, MD Howard Hughes Medical InstituteUniversity of British Columbia Chief, Diagnostics Philadelphia, Pennsylvania • Check (payable through U.S. banks only)Vancouver, British Columbia Evaluation Branch • Money OrderCanada Cancer Diagnosis Program George W. Sledge, Jr., MD • Credit Cards (MasterCard, VISA, and American Express) National Cancer Institute Ballve-Lantero Professor of OncologyMartin Brown, DPhil Rockville, Maryland Co-Director, Breast Cancer Program • Cash (on-site registration only)Professor Indiana University Melvin andStanford University Eric Jonasch, MD Bren Simon Cancer Center A receipt and confirmation letter will be sent to you within ten working days ofDivision of Radiation and Associate Professor of Indianapolis, Indiana receipt of your fee.Cancer Biology Genitourinary Medical OncologyPalo Alto, California The University of Texas MD Douglas H. Thamm, VMC, DACVIM The full conference registration fee includes the tuition, breaks, lunch, and poster Anderson Cancer Center Assistant Professor andHelen X. Chen, MD Houston, Texas Barbara Cox Anthony Chair reception.Senior Investigator in in OncologyCancer Therapy Robert S. Kerbel, PhD Director of Clinical Research Canada Research Chair in Refund/Cancellation Policy:Evaluation Program The Animal Cancer CenterNational Cancer Institute Tumor Biology, Angiogenesis Colorado State UniversityRockville, Maryland and Anti-Angiogenic Therapy Cancer Center University of Toronto Fort Collins, Colorado The registration fee, minus a $50 administrative handling fee, is refundable if a writtenS. Gail Eckhardt, MD Professor, Molecular andProfessor and Division Head Cellular Biology Research request is received on or before January 16, 2013. No refunds will be granted after that Patrick Y. Wen, MDMedical Oncology Sunnybrook Health Sciences Professor of Neurology date. The request for a registration refund must include the tax identification number ofStapp Harlow Chair in Center/Odette Cancer Center Harvard Medical School the company or institution if registration was paid by a company or institution check.Cancer Research Toronto, Ontario, Canada Director, Center for Neuro-OncologyUniversity of Colorado Denver Corey J. Langer, MD Dana Farber Cancer Institute The Department of CME/Conference Management reserves the right to cancel activitiesAurora, Colorado Boston, Massachusetts prior to the scheduled date, if low enrollment or other circumstances make it necessary. Professor of MedicineLee M. Ellis, MD University of Pennsylvania Max S. Wicha, MD Each registrant will be notified by mail, e-mail, or the contact numbers as given on theProfessor of Surgery and Perelman Center forCancer Biology Advanced Medicine Professor registration form. Department of Internal MedicineWilliam C. Liedtke, Jr. Chair Philadelphia, Pennsylvania Director In case of activity cancellation, liability of the Department of CME/Conference Managementin Cancer Research University of MichiganThe University of Texas Amita Patnaik, MD is limited to the registration fee. CME/Conference Management will refund the full Associate Director of Comprehensive Cancer CenterMD Anderson Cancer Center Clinical Reserarch Ann Arbor, Michigan registration fee. The Department of CME/Conference Management reserves the right to limitHouston, Texas the number of participants in a program and is not responsible for any expenses incurred by an START James C. Yao, MDBradley J. Erickson, MD, PhD San Antonio, Texas individual whose registration is not confirmed and for whom space is not available. Associate ProfessorAssociate Professor of Lee S. Rosen, MD GI Medical OncologyRadiology and Informatics Professor of Clinical Medicine The University of Texas For additional information, contact CME/Conference Management at 713-792-2223 orMayo Medical School Division of Hematology-Oncology MD Anderson Cancer Center toll free at 866-849-5866.Mayo Clinic University of California Houston, TexasRochester, Minnesota Los Angeles, California
Recent Advances and Future Directions in Basic and Clinical Cancer Research Department of CME/Conference Management–Unit 1381 The University of Texas MD Anderson Cancer Center The University of Texas MD Anderson Cancer Center Department Chair should verify Trainee status The 15th International Symposium on Anti-Angiogenic Therapy: ___________________________________ Registration also available on-lineSpecial Assistance Make check or money order payable to: 1 Postmarked by 1/16/13............. $ 275.00 1 Postmarked after 1/16/13......... $ 325.00 1 Postmarked by 1/16/13............ $ 100.00 1 Postmarked after 1/16/13........ $ 150.00 1 Trainee Submitting Poster..... $ 50.00 PO Box 301439, Houston, TX 77230-1439 THIS IS NOT A SELF-MAILERContact the Department of CME/Conference Management at 713-792-2223 or toll or fax to 713-794-1724free at 866-849-5866 if you have any special dietary or ADA accommodation needs. ADDRESS TO: www.antiangio2013.com REGISTRATION FEESAccommodations by signing below:• A block of rooms has been reserved for conference attendees at the Hyatt Regency La Jolla, 3777 La Jolla Village Drive, San Diego, California. Trainees:• Early hotel reservation is suggested.• The hotel reservations number is 858-552-1234.• When you make reservations be sure to mention the MD Anderson 15th International Symposium on Anti-Angiogenic Agents to be assured of receiving the special meeting rate of $215.00 single or double occupancy. Recent Advances and Future Directions in Basic and Clinical Cancer Research, January 31–February 2, 2013 MD Anderson Employee ID No. (REQUIRED) Please add 12.5% California state and local taxes. Reservations and State/Foreign Country/Zip or Mail Code Expiration Date deposits received after December 28, 2012 will be confirmed if space is Highest Degree available and at current hotel published guest room rates. o Yes o No Phone (with area code) Credit Card Holder Billing Address & ZIP Code Cell Phone (with area code) Fax (with area code)Ground Transportation The 15th International Symposium on Anti-Angiogenic Therapy: oAmerican ExpressThe hotel is approximately 20 miles from the San Diego International Airport. Taxi Physician IDT Approver E-mail Specialtyrates are approximately $45 one way. MI Credit Card Number or MD Anderson Interdepartmental Transfer (IDT) No. CONFERENCE REGISTRATION - 0597 Emergency Contact Authorized Signature REQUIRED for credit card or IDT oVISA oMasterCard First City IDT Approver Name (First/Last) please printThe University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who isin a position to control the content of an educational activity must disclose all relevant financial relationshipswith any commercial interest that could potentially affect the information presented. MD Anderson also Credit Card Holder Name (First/Last)requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of Daytime Phone (with area code)pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the Department (include box no.)educational activity.Agendas are subject to change because we are always striving to improve the quality of your educational Charge the following:experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitatedby illness, scheduling conflicts, and so forth. E-mail AddressPhotographing, audio taping and videotaping are prohibited. Last Name Institution StreetPlease let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity.Fax or e-mail CME/Conference Management. All responses will be forwarded to the Program Chairs for consideration.
Department of CME/Conference Management - Unit 1381 Non-Profit Org.The University of Texas MD Anderson Cancer Center U.S. Postage# 176700/110501 PAIDPO Box 301439 Houston, TXHouston, TX 77230-1439 Permit No. 7052